Barclays
ICCM icon

Barclays’s IceCure Medical ICCM Stock Holding History

Barclays’s Portfolio ICCM Stock Details ICCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-603
Closed -$9.78K – 5277
2023
Q3 		$9.78K Hold
603
– – ﹤0.01% 4306
2023
Q2 		$21K Buy
+603
New +$21.6K ﹤0.01% 4127

Other funds holding ICCM

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
AWM
AE Wealth Management Topeka, Kansas $18.5B AUM 19.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Barclays's ICCM Position: Q4 2023 in Review

Barclays sold out of IceCure Medical (ICCM) in Q4 2023, closing a stake of 603 shares — an estimated $9.78K sold.

Barclays first reported a position in ICCM in Q2 2023 and held it in 2 quarters. The position peaked at $21K in Q2 2023. 17 funds tracked by Wall St. Rank hold ICCM as of Q4 2023.

  • Barclays reported no remaining IceCure Medical position as of Q4 2023 after selling out during the quarter.
  • Barclays sold 603 IceCure Medical shares in Q4 2023, an estimated $9.78K.
  • Barclays first reported a position in IceCure Medical in Q2 2023 and held it in 2 quarters.
  • Barclays's IceCure Medical position peaked at $21K in Q2 2023.
  • 17 funds tracked by Wall St. Rank held IceCure Medical as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.